Therapeutic utility of EC359 for targeting oncogenic LIFR signaling in triple negative breast cancer

被引：0
|
作者：
Viswanadhapalli, Suryavathi [1 ]
Li, Mengxing [1 ]
Luo, Yiliao [1 ]
Sareddy, Gangadhara R. [1 ]
Santhamma, Bindu [2 ]
Zhou, Mei [3 ]
Ma, Shihong [4 ]
Sonavane, Rajni [4 ]
Pratap, Uday P. [1 ]
Altwegg, Kristin A. [1 ]
Chang, Annabel [4 ]
Chavez-Riveros, Alejandra [5 ]
Dileep, Kalarickal V. [6 ]
Zhang, Kam Y. [6 ]
Bajda, Marek [7 ]
Raj, Ganesh V. [4 ]
Brenner, Andrew [1 ]
Manthati, Vijaya [2 ]
Rao, Manjeet [8 ]
Tekmal, Rajeshwar R. [1 ]
Nair, Hareesh B. [2 ]
Nickisch, Klaus J. [2 ]
Vadlamudi, Ratna K. [1 ]
机构：
[1] UT Hlth Sci Ctr San Antonio, San Antonio, TX USA
[2] Evestra Inc, San Antonio, TX USA
[3] Second Xiangya Hosp, San Antonio, TX USA
[4] UT Southwestern, Dallas, TX USA
[5] Inst Quim, Mexico City, DF, Mexico
[6] RIKEN, Ctr Biosyst Dynam Res, Yokohama, Kanagawa, Japan
[7] Jagiellonian Univ, Coll Med, Krakow, Poland
[8] Greehey Childrens Canc Res Inst, San Antonio, TX USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-4716
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4716
引用
收藏
页数：2
相关论文
共 50 条
  • [1] EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer
    Viswanadhapalli, Suryavathi
    Luo, Yiliao
    Sareddy, Gangadhara R.
    Santhamma, Bindu
    Zhou, Mei
    Li, Mengxing
    Ma, Shihong
    Sonavane, Rajni
    Pratap, Uday P.
    Altwegg, Kristin A.
    Li, Xiaonan
    Chang, Annabel
    Chavez-Riveros, Alejandra
    Dileep, Kalarickal, V
    Zhang, Kam Y. J.
    Pan, Xinlei
    Murali, Ramachandran
    Bajda, Marek
    Raj, Ganesh, V
    Brenner, Andrew J.
    Manthati, Vijaya
    Rao, Manjeet K.
    Tekmal, Rajeshwar R.
    Nair, Hareesh B.
    Nickisch, Klaus J.
    Vadlamudi, Ratna K.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (08) : 1341 - 1354
  • [2] Development of a first-in-class small molecule inhibitor (EC359) targeting oncogenic LIF/LIFR signaling for the treatment of triple negative breast cancer
    Viswanadhapalli, S.
    Luo, Y.
    Sareddy, G. R.
    Santhamma, B.
    Zhou, M.
    Li, M.
    Pratap, U. P.
    Altwegg, K. A.
    Li, X.
    Srinivasan, U.
    Ma, S.
    Chang, A.
    Riveros, A. C.
    Zhang, K. Y.
    Dileep, K. V.
    Pan, X.
    Murali, R.
    Bajda, M.
    Raj, G.
    Brenner, A.
    Manthati, V.
    Rao, M.
    Tekmal, R. R.
    Nair, H. B.
    Nickisch, K. J.
    Vadlamudi, R. K.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [3] The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling
    Spencer, Nicole
    Rodriguez Sanchez, Alondra Lee
    Gopalam, Rahul
    Subbarayalu, Panneerdoss
    Medina, Daisy M.
    Yang, Xue
    Ramirez, Paulina
    Randolph, Lois
    Aller, Emily Jean
    Santhamma, Bindu
    Rao, Manjeet K.
    Tekmal, Rajeshwar Rao
    Nair, Hareesh B.
    Kost, Edward R.
    Vadlamudi, Ratna K.
    Viswanadhapalli, Suryavathi
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (24)
  • [4] Development of LIFR inhibitor EC359 as a novel therapeutic for ovarian cancer
    Viswanadhapalli, Suryavathi
    Nair, Hareesh B.
    Santhamma, Bindu
    Sareddy, Gangadhara R.
    Luo, Yiliao
    Pan, Xinlei
    Kost, Edward R.
    Murali, Ramachandran
    Tekmal, Rajeshwar Rao
    Nickisch, Klaus J.
    Vadlamudi, Ratna K.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [5] Targeting LIF/LIFR autocrine loops with EC359 in ovarian cancer: A novel LIFR targeted therapy
    Ebrahimi, Behnam
    Viswanadhapalli, Suryavathi
    Pratap, Uday P.
    Gopalam, Rahul
    Yang, Xue
    Santhamma, Bindhu
    Konda, Swapna
    Li, Xiaonan
    Yan, Hui
    Sareddy, Gangadhara R.
    Xu, Zhenming
    Kost, Edward R.
    Tekmal, Rajeshwar R.
    Nair, Hareesh B.
    Vadlamudi, Ratna K.
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [6] The LIFR-targeting small molecules EC330/EC359 are potent ferroptosis inducers
    Feng, Chang-Zhou
    Li, Ning-Zhe
    Hu, Xi-Bo
    Xie, Yin -Yin
    Huang, Qiu-Hua
    Zhang, Jianming
    Chen, Zhu
    Chen, Sai-Juan
    Wang, Fudi
    Sun, Xiao-Jian
    [J]. GENES & DISEASES, 2023, 10 (03) : 735 - 738
  • [7] Therapeutic targeting of endometrial cancer with novel LIFR inhibitor EC359.
    Tang, Weiwei
    Ramasamy, Kumaraguruparan
    Pillai, Sureshkumar M.
    Santhamma, Bindu
    Konda, Swapna
    Vekata, Prabhakar P.
    Blankenship, Logan
    Liu, Junhao
    Liu, Zexuan
    Altwegg, Kristin A.
    Ebrahimi, Behnam
    Pratap, Uday P.
    Li, Xiaonan
    Kost, Edward
    Sareddy, Gangadhara R.
    Vadlamudi, Ratna K.
    Nair, Hareesh B.
    Tekmal, Rajeshwar R.
    Viswanadhapalli, Suryavathi
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [8] The role of obesity in promoting the LIF/LIFR signaling in triple negative breast cancer
    Randolph, Lois
    Sanchez, Alondra Rodriguez
    Blankenship, Logan
    Pratap, Uday P.
    Yang, Xue
    Panneerdoss, Durga Meenakshi
    Konda, Swapna
    Santhamma, Bindu
    Sareddy, Gangadhara R.
    Rao, Manjeet K.
    Kost, Edward R.
    Tekmal, Rajeshwar R.
    Nair, Hareesh B.
    Vadlamudi, Ratna K.
    Viswanadhapalli, Suryavathi
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [9] EC359, A new therapeutic drug for the treatment of low grade serous ovarian cancer
    Lyons, Yasmin
    Arnold, William Cole
    Ebrahimi, Behnam
    Santhamma, Bindu
    Kost, Edward R.
    Nair, Hareesh B.
    Viswanadhapalli, Suryavathi
    Vadlamudi, Ratna K.
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [10] Targeting LIFR enhances the activity of HDAC inhibitors for the treatment of triple negative breast cancer
    Viswanadhapalli, Suryavathi
    Li, Mengxing
    Santhamma, Bindu
    Pratap, Uday P.
    Luo, Yiliao
    Liu, Junhao
    Altwegg, Kristin A.
    Li, Xiaonan
    Yan, Hui
    Xu, Zhenming
    Brenner, Andrew
    Sareddy, Gangadhara R.
    Tekmal, Rajeshwar R.
    Nair, Hareesh B.
    Nickisch, Klaus J.
    Vadlamudi, Ratna K.
    [J]. CANCER RESEARCH, 2020, 80 (04)
12345